vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and WATTS WATER TECHNOLOGIES INC (WTS). Click either name above to swap in a different company.
WATTS WATER TECHNOLOGIES INC is the larger business by last-quarter revenue ($625.1M vs $598.7M, roughly 1.0× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 13.4%, a 27.5% gap on every dollar of revenue. On growth, WATTS WATER TECHNOLOGIES INC posted the faster year-over-year revenue change (15.7% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $140.3M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 4.6%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
AERCO International, Inc. is a manufacturer and supplier of commercial condensing boilers, high efficiency water heating equipment and energy recovery systems in the HVAC/plumbing industry across a variety of markets including education, lodging, government, office buildings, healthcare, industrial and multifamily housing. In 1949, AERCO introduced the industry's first semi-instantaneous, tankless steam-to-water water heater. In 1988, AERCO introduced the first condensing and fully modulating...
EXEL vs WTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $625.1M |
| Net Profit | $244.5M | $83.7M |
| Gross Margin | 95.6% | 49.5% |
| Operating Margin | 39.3% | 18.2% |
| Net Margin | 40.8% | 13.4% |
| Revenue YoY | 5.6% | 15.7% |
| Net Profit YoY | 74.8% | 24.0% |
| EPS (diluted) | $0.89 | $2.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $625.1M | ||
| Q3 25 | $568.3M | $611.7M | ||
| Q2 25 | $555.4M | $643.7M | ||
| Q1 25 | $566.8M | $558.0M | ||
| Q4 24 | — | $540.4M | ||
| Q3 24 | $539.5M | $543.6M | ||
| Q2 24 | $637.2M | $597.3M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $83.7M | ||
| Q3 25 | $184.8M | $82.2M | ||
| Q2 25 | $159.6M | $100.9M | ||
| Q1 25 | $139.9M | $74.0M | ||
| Q4 24 | — | $67.5M | ||
| Q3 24 | $118.0M | $69.1M | ||
| Q2 24 | $226.1M | $82.0M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 49.5% | ||
| Q3 25 | 96.6% | 48.8% | ||
| Q2 25 | 96.5% | 50.6% | ||
| Q1 25 | 96.5% | 48.8% | ||
| Q4 24 | — | 46.7% | ||
| Q3 24 | 96.8% | 47.3% | ||
| Q2 24 | 97.2% | 47.7% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 18.2% | ||
| Q3 25 | 37.6% | 18.2% | ||
| Q2 25 | 33.6% | 21.0% | ||
| Q1 25 | 28.8% | 15.7% | ||
| Q4 24 | — | 16.5% | ||
| Q3 24 | 25.2% | 17.1% | ||
| Q2 24 | 43.3% | 18.7% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 13.4% | ||
| Q3 25 | 32.5% | 13.4% | ||
| Q2 25 | 28.7% | 15.7% | ||
| Q1 25 | 24.7% | 13.3% | ||
| Q4 24 | — | 12.5% | ||
| Q3 24 | 21.9% | 12.7% | ||
| Q2 24 | 35.5% | 13.7% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $2.50 | ||
| Q3 25 | $0.65 | $2.45 | ||
| Q2 25 | $0.55 | $3.01 | ||
| Q1 25 | $0.47 | $2.21 | ||
| Q4 24 | — | $2.02 | ||
| Q3 24 | $0.40 | $2.06 | ||
| Q2 24 | $0.77 | $2.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $405.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $2.0B |
| Total Assets | $2.8B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $405.5M | ||
| Q3 25 | $791.1M | $457.7M | ||
| Q2 25 | $1.0B | $369.3M | ||
| Q1 25 | $1.1B | $336.8M | ||
| Q4 24 | — | $386.9M | ||
| Q3 24 | $1.2B | $303.9M | ||
| Q2 24 | $1.0B | $279.4M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $2.0B | ||
| Q3 25 | $2.0B | $2.0B | ||
| Q2 25 | $2.1B | $1.9B | ||
| Q1 25 | $2.2B | $1.8B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $2.3B | $1.7B | ||
| Q2 24 | $2.1B | $1.6B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $2.9B | ||
| Q3 25 | $2.7B | $2.7B | ||
| Q2 25 | $2.8B | $2.6B | ||
| Q1 25 | $2.9B | $2.5B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | $3.0B | $2.4B | ||
| Q2 24 | $2.8B | $2.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $154.7M |
| Free Cash FlowOCF − Capex | $332.4M | $140.3M |
| FCF MarginFCF / Revenue | 55.5% | 22.4% |
| Capex IntensityCapex / Revenue | 0.2% | 2.3% |
| Cash ConversionOCF / Net Profit | 1.36× | 1.85× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $356.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $154.7M | ||
| Q3 25 | $49.0M | $122.4M | ||
| Q2 25 | $211.4M | $69.7M | ||
| Q1 25 | $240.3M | $55.2M | ||
| Q4 24 | — | $139.5M | ||
| Q3 24 | $271.3M | $90.7M | ||
| Q2 24 | $119.5M | $85.3M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $140.3M | ||
| Q3 25 | $46.2M | $110.9M | ||
| Q2 25 | $208.5M | $59.5M | ||
| Q1 25 | $236.3M | $45.6M | ||
| Q4 24 | — | $127.5M | ||
| Q3 24 | $263.1M | $84.3M | ||
| Q2 24 | $113.0M | $78.5M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 22.4% | ||
| Q3 25 | 8.1% | 18.1% | ||
| Q2 25 | 37.5% | 9.2% | ||
| Q1 25 | 41.7% | 8.2% | ||
| Q4 24 | — | 23.6% | ||
| Q3 24 | 48.8% | 15.5% | ||
| Q2 24 | 17.7% | 13.1% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 2.3% | ||
| Q3 25 | 0.5% | 1.9% | ||
| Q2 25 | 0.5% | 1.6% | ||
| Q1 25 | 0.7% | 1.7% | ||
| Q4 24 | — | 2.2% | ||
| Q3 24 | 1.5% | 1.2% | ||
| Q2 24 | 1.0% | 1.1% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 1.85× | ||
| Q3 25 | 0.27× | 1.49× | ||
| Q2 25 | 1.32× | 0.69× | ||
| Q1 25 | 1.72× | 0.75× | ||
| Q4 24 | — | 2.07× | ||
| Q3 24 | 2.30× | 1.31× | ||
| Q2 24 | 0.53× | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
WTS
Segment breakdown not available.
